Published online before print December 6, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,1
* The Holden Comprehensive Cancer Center and Departments of
Internal Medicine and
Urology, University of Iowa, Iowa City
1 Correspondence: Holden Cancer Center at The University of Iowa, 5970Z JPP, University of Iowa, Iowa City, IA 52242. E-mail: george-weiner{at}uiowa.edu
Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.
Key Words: B-CLL • cytogenetic status • CpG ODN • caspase
This article has been cited by other articles:
 |
|
 |
|
  V. Damiano, S. Garofalo, R. Rosa, R. Bianco, R. Caputo, T. Gelardi, G. Merola, L. Racioppi, C. Garbi, E. R. Kandimalla, et al. A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action Clin. Cancer Res., November 15, 2009; 15(22): 6921 - 6930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hagn, E. Schwesinger, V. Ebel, K. Sontheimer, J. Maier, T. Beyer, T. Syrovets, Y. Laumonnier, D. Fabricius, T. Simmet, et al. Human B Cells Secrete Granzyme B When Recognizing Viral Antigens in the Context of the Acute Phase Cytokine IL-21 J. Immunol., August 1, 2009; 183(3): 1838 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chiron, I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego Toll-like receptors: lessons to learn from normal and malignant human B cells Blood, September 15, 2008; 112(6): 2205 - 2213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Paone, D. Starace, R. Galli, F. Padula, P. De Cesaris, A. Filippini, E. Ziparo, and A. Riccioli Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-{alpha}-dependent mechanism Carcinogenesis, July 1, 2008; 29(7): 1334 - 1342. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gowda, J. Roda, S.-R. A. Hussain, A. Ramanunni, T. Joshi, S. Schmidt, X. Zhang, A. Lehman, D. Jarjoura, W. E. Carson, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro Blood, May 1, 2008; 111(9): 4723 - 4730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Secchiero, E. Melloni, M. Tiribelli, A. Gonelli, and G. Zauli Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells J. Leukoc. Biol., February 1, 2008; 83(2): 434 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Leonard, B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et al. Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma Clin. Cancer Res., October 15, 2007; 13(20): 6168 - 6174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself J. Immunol., August 15, 2007; 179(4): 2493 - 2500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jahrsdorfer, S. E. Blackwell, J. E. Wooldridge, J. Huang, M. W. Andreski, L. S. Jacobus, C. M. Taylor, and G. J. Weiner B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation Blood, October 15, 2006; 108(8): 2712 - 2719. [Abstract] [Full Text] [PDF]
|
|
